Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY.
Clin Breast Cancer. 2024 Oct;24(7):585-596. doi: 10.1016/j.clbc.2024.06.005. Epub 2024 Jun 12.
Breast Cancer Index (BCI) is a genomic assay that evaluates the benefit of extending endocrine therapy (ET) from 5 to 10 years and predicts recurrence risk (RR). We evaluated the association between BCI and Oncotype DX (ODX).
Women with hormone receptor (HR)-positive early-stage breast cancer (EBC) who had BCI and ODX performed were included.
We performed a retrospective review of women with HR-positive EBC. BCI was categorized as predictive of extended ET versus not and ODX recurrence score (RS) as low (0-10), intermediate (11-25), and high (26-100). Univariate and multivariable logistic and linear regression models assessed the relationship between BCI and ODX, factors associated with each, and discordance between scores.
We identified 153 women, 22% were premenopausal and 18% were lymph node positive. The univariate logistic and linear models revealed an association between BCI predictive score and ODX RS (OR 7.84, CI, 2.63-23.36, P < .001) and log of BCI RR (Beta 0.04, CI, 0.02-0.06, P < .001). Seventy-four percent of BCI predictive scores were concordant with ODX RS and 83% of BCI RR was concordant with ODX RR. In a univariate logistic regression model, BCI predictive of ET benefit was associated with discordance (OR 28.00, CI, 10.58-74.02, P < .001). Higher ODX RR was associated with discordance (OR 1.92, CI, 1.42-2.59, P < .001).
We found a significant association between ODX and BCI predictive and prognostic scores. BCI predictive of extended ET benefit was associated with discordance with ODX RS. Higher predicted RR on ODX was associated with discordance with BCI predicted RR.
乳腺癌指数（BCI）是一种基因组检测，可评估将内分泌治疗（ET）从 5 年延长至 10 年的获益，并预测复发风险（RR）。我们评估了 BCI 与 Oncotype DX（ODX）之间的关联。
入组患者为接受 BCI 和 ODX 检测的激素受体（HR）阳性早期乳腺癌（EBC）女性。
我们对 HR 阳性 EBC 女性进行了回顾性研究。BCI 分为预测 ET 获益和不获益，ODX 复发评分（RS）分为低（0-10）、中（11-25）和高（26-100）。单变量和多变量逻辑和线性回归模型评估了 BCI 和 ODX 之间的关系、与每个指标相关的因素，以及评分之间的差异。
我们共纳入 153 名女性，22%为绝经前，18%为淋巴结阳性。单变量逻辑和线性模型显示，BCI 预测评分与 ODX RS（OR 7.84，CI，2.63-23.36，P<0.001）和 BCI RR 的对数（Beta 0.04，CI，0.02-0.06，P<0.001）之间存在关联。BCI 预测评分与 ODX RS 之间有 74%的一致性，BCI RR 与 ODX RR 之间有 83%的一致性。在单变量逻辑回归模型中，BCI 预测对 ET 获益与差异相关（OR 28.00，CI，10.58-74.02，P<0.001）。较高的 ODX RR 与差异相关（OR 1.92，CI，1.42-2.59，P<0.001）。
我们发现 ODX 与 BCI 预测和预后评分之间存在显著关联。BCI 预测 ET 获益与 ODX RS 不一致。ODX 预测 RR 较高与 BCI 预测 RR 不一致。
